This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,279,005 to The Johns Hopkins University to conduct research on hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional silencing, with a focus on comparing HBV mono-infection and HBV/HIV co-infection. The 5-year project aims to uncover the mechanisms underlying cccDNA transcriptional...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $814,790 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the immune mechanisms underlying hepatitis B virus (HBV) surface antigen (HBsAg) clearance in chronic HBV patients. The research aims to uncover parallels between mouse models and clinical studies of HBsAg clearance,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,764 to The Trustees of Princeton University to conduct research aimed at disrupting the formation of HBV cccDNA to combat chronic HBV infection, particularly in the context of HIV co-infection. The key objectives are to: 1) determine whether genetic disruption of host factors involved in HBV cccDNA...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $681,278 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant, which runs from July 2024 to May 2026, will fund research to characterize the HIV latent reservoir and model the contributions of antigen-driven and homeostatic proliferation to its persistence in people living with HIV on antiretroviral therapy. The goal is to help design future HIV...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 2-year Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) worth $162,000 to The Johns Hopkins University to study how atypical B cells can be used to enhance vaccine responses in immunosuppressed individuals. The research project aims to define populations of immunosuppressed individuals who utilize these atypical CD11c+ B cells, assess their interaction with T cells, and target fatty acid oxidation...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $621,698 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Southern California. The goal of this 5-year research project is to investigate how hepatitis B virus (HBV) transmitted from infected mothers to their children affects the offspring's immune response and promotes chronic HBV infection. The researchers will identify specific maternal HBV factors that enable...
This Project Grant award of $153,512.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Emory University to investigate the mechanistic origins of liver-resident plasma cells arising during acute hepatitis C virus (HCV) infection. The goal is to determine how and where these plasma cells are generated, as understanding their immunological origins could inform the rational design...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $3,056,673 to The Johns Hopkins University to conduct research on the immunologic mechanisms associated with hepatitis B (HBV) vaccine responses in people living with HIV (PLWH).
The key objectives are to: 1) Define the innate immune signatures of the HBV vaccine adjuvants CpG 1018 and alum, 2) Compare HBV-specific B and T cell responses induced by the Heplisav-B and Engerix-B vaccines, and 3) Assess the HIV reservoir and HIV-specific immune responses before and after Heplisav-B vaccination. This research aims to improve understanding of dysregulated immune responses in PLWH and inform the development of HIV curative strategies. The award period runs from July 2024 through May 2029.